Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. - Wikidata - thesis-toulmin - TriplyDB

Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

http://www.wikidata.org/entity/Q35758001

about

Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease Envelope determinants of equine lentiviral vaccine protection.Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain.Envelope variation as a primary determinant of lentiviral vaccine efficacy.Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus.Challenges and proposed solutions for more accurate serological diagnosis of equine infectious anaemia An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.Validation according to OIE criteria of a monoclonal, recombinant p26-based, serologic competitive enzyme-linked immunosorbent assay as screening method in surveillance programs for the detection of Equine infectious anemia virus antibodies.Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.A pilot study on an attenuated Chinese EIAV vaccine inducing broadly neutralizing antibodies.In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine.Prospects in Innate Immune Responses as Potential Control Strategies against Non-Primate Lentiviruses

P2860

Q21131325-41285BF3-F52E-46A3-B434-FCCAD9C7BC97 Q34133986-9E58D09A-AEBB-42E5-80FD-E63D0DBEB28D Q34380211-8A9B2C1E-9FA9-480C-90AC-A734B8291B7C Q34778836-0336B84D-2981-4AA8-A3F0-10C6AB85D1E2 Q34812619-C278D5A4-26C6-4A55-9743-C831BD6254CF Q36002639-6B62F3B1-C3A3-4C55-935F-7E53D76B86DC Q36328526-CA90B034-1B4D-4905-B54D-6238573424B6 Q36670992-7AA7843C-EA38-4964-8E66-EA5F892D53EE Q37405780-292845C1-7CBD-455A-98ED-B8061D5A815B Q37666746-2834B64E-2079-423A-A62E-F58E330DA439 Q39848883-4AC3D899-3033-4760-9A2E-48C43BBDCF06 Q40760045-88649DF8-B4C7-41A6-B897-94DA36778011 Q41759578-9D583D7D-EEBC-4A5F-9486-26B48F485445 Q41826961-2DB1904B-6416-493E-8140-DC45612067B8 Q44561674-5B8B50D2-3947-4B05-A70A-3AE9B953058A Q45385363-C654056E-C513-49AE-9DA3-B0ED675EFDC8 Q56977004-9D41FAD7-7B9B-46A6-9716-B0E1E721E611

P2860

Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

http://www.wikidata.org/entity/Q35758001

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Immune suppression of challeng ...... ection by lentiviral vaccines.

@ast

Immune suppression of challeng ...... ection by lentiviral vaccines.

@en

type

label

Immune suppression of challeng ...... ection by lentiviral vaccines.

@ast

Immune suppression of challeng ...... ection by lentiviral vaccines.

@en

prefLabel

Immune suppression of challeng ...... ection by lentiviral vaccines.

@ast

Immune suppression of challeng ...... ection by lentiviral vaccines.

@en

P1433

Q35758001-00C2AA1C-A111-48AE-B6C1-7BE109D9210C

P1476

Q35758001-C755B952-A105-4F4B-A7AA-B8FA87FB6875

P2093

Q35758001-1008C305-FFB1-431A-BE66-86FAF9E1C68D

Q35758001-1EAE85F4-D447-4CCA-AF7F-8287981B5966

Q35758001-2CC16828-6764-470D-82B4-525FC3EAC329

Q35758001-93B5769B-87E4-4FE5-A3C5-021AEE813904

Q35758001-CC9E2412-3EFC-4F87-B398-E59880A3347F

Q35758001-FB25A04A-87CD-4EA3-8A80-0E6A30CB0233

Q35758001-FCF494A8-F9E4-4752-998E-47F765D447AD

P2860

Q35758001-0C619112-6745-4542-A05A-7B802A931370

Q35758001-11E46272-3073-448C-BFBF-782F081925A5

Q35758001-168D673D-B273-4420-AB46-F2A194E54324

Q35758001-1A70B67D-3D1C-42BC-84AA-55D744B44634

Q35758001-2E989F31-7539-49D8-A195-06C9737DCF71

Q35758001-3DEC120E-E784-461A-AAC4-7D61A4B03D68

Q35758001-44DDEF88-36E8-41C5-B82E-4FBAD4E76992

Q35758001-499AE64D-CAE2-4B47-96B8-1EB663E1F895

Q35758001-4E3E0C3B-1962-474F-85E0-BD9C3FD14E68

Q35758001-4E73C8CA-A8F9-4235-A5E0-96B588DAB73A

P304

Q35758001-1DDCB363-7F2B-4AC4-B1C9-D0E41AA0B316

P31

Q35758001-C13257AF-012A-46F4-A3E0-2A34E2BA0305

P356

Q35758001-57553663-57F7-48AB-9C54-1B03A2CFB451

P407

Q35758001-37CE15C7-FE07-46F8-9EC0-543C7DEAE29E

P433

Q35758001-EB753C73-143B-49A7-A85E-E18735C75A52

P478

Q35758001-82011D2F-20C5-41F9-85DA-2E089636394D

P577

Q35758001-B3FAA1AA-362A-4534-9C52-1B8D6722B889

P5875

Q35758001-D9046E81-081D-4CDF-A991-0C9F2AD8932C

P698

Q35758001-A20FE649-A94B-4AB3-8C23-A72A99B81A3E

P932

Q35758001-FFB76FEB-AF75-4F5C-856B-F77286DCA771

P356

J.VACCINE.2006.09.040

P1433

P1476

Immune suppression of challeng ...... ection by lentiviral vaccines.

@en

P2093

Charles J Issel

http://www.w3.org/2001/XMLSchema#string

Jodi K Craigo

http://www.w3.org/2001/XMLSchema#string

Ronald C Montelaro

http://www.w3.org/2001/XMLSchema#string

Shannon Durkin

http://www.w3.org/2001/XMLSchema#string

Sheila J Cook

http://www.w3.org/2001/XMLSchema#string

Tara Tagmyer

http://www.w3.org/2001/XMLSchema#string

Timothy J Sturgeon

http://www.w3.org/2001/XMLSchema#string

P2860

Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy

A tumor necrosis factor receptor family protein serves as a cellular receptor for the macrophage-tropic equine lentivirus.

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.

Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement.

Live attenuated SIV--a model of a vaccine for AIDS.

Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.

The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro

Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids

Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus.

Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.

P304

834-845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2006.09.040

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6772151

http://www.w3.org/2001/XMLSchema#string

P698

17023099

http://www.w3.org/2001/XMLSchema#string

P932

1855206

http://www.w3.org/2001/XMLSchema#string